Author: backoffice

Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11;14) multiple myeloma

A BCL-2 inhibitor named as venetoclax which was initially given FDA approval. Proteins significantly regulate the apoptotic process from the B cell CLL or lymphoma families. Venetoclax treats some forms of small lymphocytic lymphoma and chronic lymphocytic leukemia. In Western nations, CLL is the most common leukemia to be diagnosed. The BCL-2 protein family inhibitor, […]
Read More